Nefrologia · 2026
New strategies to empower patients with chronic kidney disease in phosphorus control (empower-PHOS).
СтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arenas Jiménez María Dolores, García de Polavieja María Delgado, Escribano Soraya, Audije-Gil Julia, Sánchez-Tocino María Luz, Henríquez-Palop Fernando, Antón Pérez Gloria, Yetman Delfina, Pereira Mónica, Molina Pablo, Auxiliadora Bajo María, Jesús Lloret María, Quilis Aina, Fernández Carlos, García Monteavaro Camino, María León Lina, Botella Ana, Ballart Judith, Durbá Alba, Furaz Karina, González Parra Emilio, Handel Marc, Delgado Yagüe María, Antonio Herrero José, Dapena Bielva Fabiola, Grupo de trabajo Empower-PHOS
Аннотация
INTRODUCTION: Serum phosphorus (P) control in hemodialysis (HD) remains a major challenge, largely influenced by phosphate binder adherence and patient engagement. Structured educational strategies may enhance self-care and improve clinical outcomes.
OBJECTIVE: To evaluate the effectiveness of a patient-centered educational intervention for phosphorus control in hemodialysis.
MATERIAL AND METHODS: Multicenter, prospective, randomized clinical trial including patients with hyperphosphatemia or high binder requirements, allocated to an intervention group (structured education + Empower-PHOS tool) or a control group (standard care). Serum P, binder dose, and adherence (SMAQ) were assessed at baseline and at 3, 6, and 12 months.
RESULTS: Both groups were comparable at baseline. A total of 122 patients from 14 centers were enrolled. The intervention group achieved significant reductions in serum P at 3 months (from 6.1 to 5.4 mg/dl; p < .001) and at 12 months (from 6.2 to 5.2 mg/dl; p = .010), without changes in the number of pills or daily binder dose. Improvements were observed in both adherent and non-adherent patients, with particularly notable reductions among the latter (from 6.4 ± 1.2 to 5.8 ± 1.2 mg/dl; p = .015). Adherence according to SMAQ did not change significantly.
CONCLUSIONS: A structured, patient-centered educational intervention improved phosphorus control in hemodialysis, even among patients with low baseline adherence, without increasing the pharmacological burden. These findings support the integration of personalized educational strategies as a key component in the comprehensive management of hyperphosphatemia in routine hemodialysis practice.
OBJECTIVE: To evaluate the effectiveness of a patient-centered educational intervention for phosphorus control in hemodialysis.
MATERIAL AND METHODS: Multicenter, prospective, randomized clinical trial including patients with hyperphosphatemia or high binder requirements, allocated to an intervention group (structured education + Empower-PHOS tool) or a control group (standard care). Serum P, binder dose, and adherence (SMAQ) were assessed at baseline and at 3, 6, and 12 months.
RESULTS: Both groups were comparable at baseline. A total of 122 patients from 14 centers were enrolled. The intervention group achieved significant reductions in serum P at 3 months (from 6.1 to 5.4 mg/dl; p < .001) and at 12 months (from 6.2 to 5.2 mg/dl; p = .010), without changes in the number of pills or daily binder dose. Improvements were observed in both adherent and non-adherent patients, with particularly notable reductions among the latter (from 6.4 ± 1.2 to 5.8 ± 1.2 mg/dl; p = .015). Adherence according to SMAQ did not change significantly.
CONCLUSIONS: A structured, patient-centered educational intervention improved phosphorus control in hemodialysis, even among patients with low baseline adherence, without increasing the pharmacological burden. These findings support the integration of personalized educational strategies as a key component in the comprehensive management of hyperphosphatemia in routine hemodialysis practice.